Oklo (OKLO) is down about 4% as the stock gives back recent gains in the absence of a new catalyst, following closely watched March updates tied to the company’s Idaho National Laboratory workstream. The most recent company-level positive development was the March 17, 2026 announcement that the DOE Idaho Operations Office approved a Nuclear Safety Design Agreement and that Oklo requested DOE commence review of its Preliminary Documented Safety Analysis—an item investors had treated as a milestone, but one that does not immediately change near-term revenue timing.

Oklo remains a development-stage, pre-revenue story where near-term valuation is sensitive to timelines and funding perceptions, so price action can swing sharply when news flow slows. Adding to caution, recent insider selling has been a visible overhang in March, with multiple reported sales by senior executives earlier in the month, reinforcing the market’s tendency to fade rallies after milestone headlines rather than re-rate the stock higher on incremental process steps.

The next key swing factor is regulatory progress on the NRC track for Oklo’s Aurora program, where investors are focused on expected draft evaluation timing tied to the company’s Principal Design Criteria review pathway and any follow-on communications that clarify scope, open items, or schedule risk. Traders are also watching for any update that converts milestone progress into clearer commercialization timing, customer/contract visibility, or changed cash-use expectations.